-
$100.00
-
1 mg
Description
23andMe has been researching Parkinson's disease for over 12 years. The company's Parkinson's Disease Research Program is focused on understanding the genetic and non-genetic factors that contribute to the disease. The program has over 196,000 participants and is one of the largest genetic research cohorts in the world. The goal of the program is to develop therapies to prevent or delay disease progression by detecting and monitoring early signs of Parkinson's disease. Research participants contribute to the program by answering research questions, completing surveys, and reviewing their 23andMe Parkinson's Disease Genetic Health Risk Report.
